文献速递肾小球疾病

膜性肾病治疗策略的演变

The evolution of the therapeutic approach to membranous nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

原发性膜性肾病是成人肾病综合征的常见病因,未治疗者约三分之一可缓解,其余持续蛋白尿或进展至终末期肾病。随机试验证实糖皮质激素与烷化剂隔月交替的6个月方案有效,长期随访达10年显示持久疗效与安全性。钙调神经磷酸酶抑制剂有效但停药后多复发,利妥昔单抗在两项对照试验中优于单纯抗蛋白尿治疗和环孢素,但随访较短且缺乏与周期性治疗的随机对照。

要点

  • 糖皮质激素与烷化剂隔月交替的6个月方案有长达10年随访的疗效与安全性证据。
  • 钙调神经磷酸酶抑制剂有效但停药后多数缓解者肾病综合征复发。
  • 利妥昔单抗优于单纯抗蛋白尿治疗和环孢素,但随访短且缺乏与周期性治疗的随机对照。

核心结论

  • 现有结果支持在膜性肾病中使用细胞毒药物或利妥昔单抗,但两者间选择困难,利妥昔单抗使用更方便但长期复发风险与重复给药安全性存疑。

研究设计与样本

  • 本文为综述,汇总随机临床试验、观察性研究及对照试验结果,涉及糖皮质激素联合烷化剂的周期性方案、钙调神经磷酸酶抑制剂、霉酚酸盐、促肾上腺皮质激素和利妥昔单抗等治疗。

主要发现

  • 未治疗患者中三分之一进入缓解,其余持续蛋白尿或进展至终末期肾病。
  • 6个月糖皮质激素与烷化剂隔月交替方案有效,两项随机试验随访达10年证实长期疗效与安全性。
  • 钙调神经磷酸酶抑制剂治疗有效,但多数缓解者停药后肾病综合征复发。
  • 霉酚酸盐与促肾上腺皮质激素的结果存在矛盾。
  • 利妥昔单抗在两项对照试验中优于单纯抗蛋白尿治疗和环孢素,但随访相对较短,且尚无与周期性治疗的随机试验发表。

关键数值与推荐

  • 糖皮质激素与烷化剂隔月交替方案为6个月疗程,两者各自使用不超过3个月。
  • 两项随机试验随访长达10年,提供该周期性治疗长期疗效与安全性的保证。
  • 多数膜性肾病患者存在抗磷脂酶A2受体1循环抗体,支持细胞毒药物或利妥昔单抗的使用。

临床怎么用

  • 膜性肾病患者可考虑糖皮质激素联合烷化剂的周期性方案或利妥昔单抗治疗。
  • 选择利妥昔单抗时需权衡其使用便利性与长期复发风险及重复给药安全性证据不足的问题。
  • 使用钙调神经磷酸酶抑制剂者停药后需警惕肾病综合征复发。

局限性

  • 利妥昔单抗相关研究的随访相对较短,长期复发风险与重复给药安全性仍存疑问。
  • 尚无利妥昔单抗与周期性治疗的随机对照试验发表。
  • 霉酚酸盐与促肾上腺皮质激素的研究结果存在矛盾。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary membranous nephropathy (MN) is a frequent cause of nephrotic syndrome (NS) in adults. In untreated patients, the outcome is variable, with one-third of the patients entering remission while the remaining ones show persisting proteinuria or progression to end-stage renal disease. Randomized clinical trials reported the efficacy of a 6-month regimen alternating intravenous and oral glucocorticoids with an alkylating agent every other month. The potential side effects of this regimen were limited by the fact that the use of glucocorticoids and alkylating agent did not exceed 3 months each. Two randomized trials with follow-ups (FU) up to 10 years provided assurance about the long-term efficacy and safety of this cyclical therapy. Calcineurin inhibitors have also been used successfully. However, in most responders, NS relapsed after the drug was withdrawn. Conflicting results have been reported with mycophenolate salts and adrenocorticotropic hormone. Observational studies reported good results with rituximab (RTX). Two controlled trials demonstrated the superiority of RTX over antiproteinuric therapy alone and cyclosporine. However, the FUs were relatively short and no randomized trial has been published against cyclical therapy. The available results, together with the discovery that most patients with MN have circulating antibodies against the phospholipase A2 receptor 1, support the use of cytotoxic drugs or RTX in MN. It is difficult to choose between these two different treatments. RTX is easier to use, but the FUs of the available studies are short, thus doubts remain about the long-term risk of relapses and the safety of repeated administrations of RTX.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ponticelli C, Patrizia P, Del Vecchio L, et al. The evolution of the therapeutic approach to membranous nephropathy. Nephrol Dial Transplant. 2021. PMID: 32206786. doi:10.1093/ndt/gfaa014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。